Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer
Aonghus Lavelle(Inserm), Harry Sokol(AgroParisTech), Stéphane Nancey, David Laharie(Université de Bordeaux), Philippe Marteau(Eaton (Taiwan)), Xavier Tréton(Hôpital Beaujon), Cyriane Oeuvray(Inserm), Laurent Beaugerie(Assistance Publique – Hôpitaux de Paris), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Matthieu Allez(Inserm), Dominique Rainteau(Inserm), Emilie Gauliard(Inserm), Nathalie Rolhion, Philippe Seksik(Inserm), Georgia Malamut(Délégation Paris 5), Julien Kirchgesner(Université Paris-Est Créteil), Xavier Dray(Sorbonne Université), Antonin Lamazière(Sorbonne Université), Jean‐Marie Reimund(Hôpital d'Hautepierre), Xavier Roblin(Centre Hospitalier Universitaire de Saint-Étienne)
Cited by 59
Related Papers
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k